E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

Hani M. Babiker, Sara A. Byron, William P.D. Hendricks, William F. Elmquist, Gautham Gampa, Jessica Vondrak, Jessica Aldrich, Lori Cuyugan, Jonathan Adkins, Valerie De Luca, Raoul Tibes, Mitesh J. Borad, Katie Marceau, Thomas J. Myers, Linda J. Paradiso, Winnie S. Liang, Ronald L. Korn, Derek Cridebring, Daniel D. Von Hoff, John D. CarptenDavid W. Craig, Jeffrey M. Trent, Michael S. Gordon

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences